117 related articles for article (PubMed ID: 16154102)
21. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
22. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension.
Vanourková Z; Kramer HJ; Husková Z; Vanecková I; Opocenský M; Chábová VC; Tesar V; Skaroupková P; Thumová M; Dohnalová M; Mullins JJ; Cervenka L
J Hypertens; 2006 Dec; 24(12):2465-72. PubMed ID: 17082731
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
Bayorh MA; Ganafa AA; Eatman D; Walton M; Feuerstein GZ
Am J Hypertens; 2005 Nov; 18(11):1496-502. PubMed ID: 16280288
[TBL] [Abstract][Full Text] [Related]
24. Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice.
Popp L; Häussler A; Olliges A; Nüsing R; Narumiya S; Geisslinger G; Tegeder I
Eur J Pain; 2009 Aug; 13(7):691-703. PubMed ID: 18938093
[TBL] [Abstract][Full Text] [Related]
25. Rat chromosome 19 transfer from SHR ameliorates hypertension, salt-sensitivity, cardiovascular and renal organ damage in salt-sensitive Dahl rats.
Wendt N; Schulz A; Siegel AK; Weiss J; Wehland M; Sietmann A; Kossmehl P; Grimm D; Stoll M; Kreutz R
J Hypertens; 2007 Jan; 25(1):95-102. PubMed ID: 17143179
[TBL] [Abstract][Full Text] [Related]
26. The pharmacology of selective inhibition of COX-2.
Grosser T
Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
[TBL] [Abstract][Full Text] [Related]
27. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Bao W; Behm DJ; Nerurkar SS; Ao Z; Bentley R; Mirabile RC; Johns DG; Woods TN; Doe CP; Coatney RW; Ohlstein JF; Douglas SA; Willette RN; Yue TL
J Cardiovasc Pharmacol; 2007 Jun; 49(6):362-8. PubMed ID: 17577100
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function.
Egecioglu E; Andersson IJ; Bollano E; Palsdottir V; Gabrielsson BG; Kopchick JJ; Skott O; Bie P; Isgaard J; Bohlooly-Y M; Bergström G; Wickman A
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1418-25. PubMed ID: 17244725
[TBL] [Abstract][Full Text] [Related]
29. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene.
Watanabe H; Katoh T; Eiro M; Iwamoto M; Ushikubi F; Narumiya S; Watanabe T
Circ J; 2005 Jan; 69(1):124-6. PubMed ID: 15635218
[TBL] [Abstract][Full Text] [Related]
30. Is prostacyclin an inodilator?
Ricksten SE
Intensive Care Med; 2003 Sep; 29(9):1403-5. PubMed ID: 12904857
[No Abstract] [Full Text] [Related]
31. COX-2 inhibitors may raise blood pressure.
Health News; 2005 Jun; 11(6):2. PubMed ID: 16127788
[No Abstract] [Full Text] [Related]
32. Prostanoids in Cardiac and Vascular Remodeling.
Ricciotti E; Haines PG; Chai W; FitzGerald GA
Arterioscler Thromb Vasc Biol; 2024 Mar; 44(3):558-583. PubMed ID: 38269585
[TBL] [Abstract][Full Text] [Related]
33. Beraprost sodium attenuates the development of myocardial fibrosis after myocardial infarction by regulating GSK-3β expression in rats.
Li XX; Wang YZ; Liu C; Fu GW; Li J; Zhang JY
Immun Inflamm Dis; 2023 Nov; 11(11):e1050. PubMed ID: 38018586
[TBL] [Abstract][Full Text] [Related]
34. The Link between Prostanoids and Cardiovascular Diseases.
Beccacece L; Abondio P; Bini C; Pelotti S; Luiselli D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835616
[TBL] [Abstract][Full Text] [Related]
35. The Use of Aspirin Increases the Risk of Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients with Obstructive Sleep Apnea for the Primary Prevention of Cardiovascular Disease: A Real-World Cohort Study.
Li N; Wen W; Cai X; Zhu Q; Hu J; Heizhati M; Yuan Y; Gan L; Dang Y; Yang W; Hong J; Zhang X
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498638
[TBL] [Abstract][Full Text] [Related]
36. Sex-dependent compensatory mechanisms preserve blood pressure homeostasis in prostacyclin receptor-deficient mice.
Tang SY; Meng H; Anderson ST; Sarantopoulou D; Ghosh S; Lahens NF; Theken KN; Ricciotti E; Hennessy EJ; Tu V; Bittinger K; Weiljie AM; Grant GR; FitzGerald GA
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34101620
[TBL] [Abstract][Full Text] [Related]
37. Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.
Mitchell JA; Shala F; Pires MEL; Loy RY; Ravendren A; Benson J; Urquhart P; Nicolaou A; Herschman HR; Kirkby NS
Sci Adv; 2021 Mar; 7(12):. PubMed ID: 33741600
[TBL] [Abstract][Full Text] [Related]
38. Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?
Khan S; Andrews KL; Chin-Dusting JPF
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480335
[TBL] [Abstract][Full Text] [Related]
39. Complex Role for E-Prostanoid 4 Receptors in Hypertension.
Herrera M; Yang T; Sparks MA; Manning MW; Koller BH; Coffman TM
J Am Heart Assoc; 2019 Feb; 8(4):e010745. PubMed ID: 30764697
[TBL] [Abstract][Full Text] [Related]
40. Endothelial prostacyclin protects the kidney from ischemia-reperfusion injury.
Cao Y; Guan Y; Xu YY; Hao CM
Pflugers Arch; 2019 Apr; 471(4):543-555. PubMed ID: 30413885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
